Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 47,814 shares of the company’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the sale, the director directly owned 3,482,888 shares of the company’s stock, valued at $155,023,344.88. The trade was a 1.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total transaction of $84,237.30.

Sionna Therapeutics Stock Down 3.8%

SION stock opened at $43.54 on Friday. The company has a market capitalization of $1.96 billion, a P/E ratio of -22.33 and a beta of 3.01. The company has a 50-day simple moving average of $37.74 and a 200 day simple moving average of $38.39. Sionna Therapeutics, Inc. has a fifty-two week low of $10.07 and a fifty-two week high of $46.46.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The company reported an EPS beat on March 2 (reported -$0.46 vs. consensus -$0.61), a fundamental datapoint that supports investor sentiment and helps explain why the stock has traded above its 50/200‑day averages.
• Positive Sentiment: Despite selling, the reporting director (Orbimed / Peter A. Thompson) still holds a very large stake (roughly 3.0–3.5M shares), which tempers the interpretation that insiders are deserting the company.
• Neutral Sentiment: Many of the reported sales were executed under pre‑arranged Rule 10b5‑1 plans, which reduces the likelihood the trades reflect new negative private information.
• Neutral Sentiment: Analyst coverage is skewed positive: multiple buy/strong‑buy ratings and an average target (~$50.6) provide a supportive backdrop for sentiment.
• Negative Sentiment: Large, consecutive insider sell filings on April 14–16 total roughly 510K shares (~$22–23M at reported prices). That scale of director selling can create short‑term downward pressure and trigger investor concern despite 10b5‑1 protections. InsiderTrades Alert SEC Filing

Analyst Upgrades and Downgrades

SION has been the topic of several research reports. Guggenheim boosted their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. BTIG Research reiterated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Citigroup initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating on the stock. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $50.57.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SION. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics in the fourth quarter worth about $26,290,000. Vanguard Group Inc. raised its holdings in Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after buying an additional 512,803 shares during the period. State Street Corp raised its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after buying an additional 453,196 shares during the period. Viking Global Investors LP raised its holdings in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the period. Finally, Millennium Management LLC raised its holdings in Sionna Therapeutics by 1,425.5% during the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock worth $6,296,000 after buying an additional 200,051 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.